Delivery Order SPE2DB22D3102-SPE2DB26FK8UR
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This firm fixed-price delivery order, issued on September 15, 2025, with an ultimate completion date of October 6, 2025, represents a non-set-aside competitive award to the prime contractor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $6,704.88 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin injection used in medical and therapeutic applications. This firm fixed price delivery order, issued on August 7, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,174.80 for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This non-set-aside, competitively awarded contract employs firm fixed pricing and is scheduled for completion by November 17, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $22,349.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The contract was competitively awarded without set-aside designation and is scheduled for completion by October 16, 2025. Performance will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a $49,461.72 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This firm fixed-price contract, awarded November 5, 2025, with completion targeted for November 28, 2025, represents a competitively awarded procurement with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company...
- The Defense Logistics Agency awarded a $1,676.22 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $23,553.20 to AmerisourceBergen Drug Corp for the supply of 200-unit vials of Xeomin, a botulinum toxin-based pharmaceutical product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on November 3, 2025, with an ultimate completion date of November 25, 2025, represents a non-competitive award without set-aside designation. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $55,874 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This firm fixed-price, competitively awarded contract is scheduled for completion by October 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation, indicating it was awarded through open competition. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,676.22 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The award, issued on August 21, 2025, with an ultimate completion date of September 12, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major...
- The Defense Logistics Agency awarded a $3,532.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used in medical and therapeutic applications. The contract, issued on October 21, 2025, with an ultimate completion date of November 12, 2025, represents a child order under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is...
- SPE2DB22D3102Indefinite Delivery Contract
- SPE2DB22D3102-SPE2DB26FK8URDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,352.44 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin injection used for medical and therapeutic purposes. The contract, awarded on November 6, 2025, with an ultimate completion date of December 1, 2025, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen supplies critical medications and medical supplies to defense and veteran healthcare systems. The company's comprehensive IDC vehicle enables it to fulfill diverse pharmaceutical requirements across multiple therapeutic domains for military healthcare programs worldwide, supporting customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 11/6/25 |